Barron takes on business development role
Eurofins AvTech Laboratories has appointed Michael Barron as director of business development.
Barron has previously worked for Catalent Pharma Solutions, Cardinal Health, and other leading contract drug development and analytical service companies.
AvTech offers analytical support for all stages of drug discovery and development from early ADME studies of drug candidates to stability and release testing of the finished product. The company places particular emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.
You may also like
Research & Development
Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications
Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies